Austin Health

Title
Implications of the 2022 lung function update and GLI global reference equations among patients with interstitial lung disease.
Publication Date
2024-10-16
Author(s)
Li, Andrew
Teoh, Alan
Troy, Lauren
Glaspole, Ian
Wilsher, Margaret L
de Boer, Sally
Wrobel, Jeremy
Moodley, Yuben P
Thien, Francis
Gallagher, Henry
Galbraith, Michelle
Chambers, Daniel C
Mackintosh, John
Goh, Nicole S L
Khor, Yet Hong
Edwards, Adrienne
Royals, Karen
Grainge, Christopher
Kwan, Benjamin
Keir, Gregory J
Ong, Chong
Reynolds, Paul N
Veitch, Elizabeth
Chai, Gin Tsen
Ng, Ziqin
Tan, Geak Poh
Jackson, Dan
Corte, Tamera
Jo, Helen
Subject
Connective tissue disease associated lung disease
Idiopathic pulmonary fibrosis
Interstitial Fibrosis
Pulmonary vasculitis
Rare lung diseases
Type of document
Journal Article
OrcId
0000-0003-1516-3454
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
0000-0002-5254-4144
#PLACEHOLDER_PARENT_METADATA_VALUE#
0000-0002-5434-9342
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
0000-0003-0758-6895
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
DOI
10.1136/thorax-2024-221813
Abstract
Lung function testing remains a cornerstone in the assessment and management of interstitial lung disease (ILD) patients. The clinical implications of the Global Lung function Initiative (GLI) reference equations and the updated interpretation strategies remain uncertain. Adult patients with ILD with baseline forced vital capacity (FVC) were included from the Australasian ILD registry and the National Healthcare Group ILD registry, Singapore.The European Coal and Steel Community and Miller reference equations were compared with the GLI reference equations to assess (a) differences in lung function percent predicted values; (b) ILD risk prediction models and (c) eligibility for ILD clinical trial enrolment. Among 2219 patients with ILD, 1712 (77.2%) were white individuals. Idiopathic pulmonary fibrosis (IPF), connective tissue disease-associated ILD and unclassifiable ILD predominated.Median FVC was 2.60 (2.01-3.36) L, forced expiratory volume in 1 s was 2.09 (1.67-2.66) L and diffusing capacity of the lungs for carbon monoxide (DLCO) was 13.60 (10.16-17.60) mL/min/mm Hg. When applying the GLI reference equations, the mean FVC percentage predicted was 8.8% lower (87.7% vs 78.9%, p<0.01) while the mean DLCO percentage predicted was 4.9% higher (58.5% vs 63.4%, p<0.01). There was a decrease in 19 IPF and 119 non-IPF patients who qualified for the nintedanib clinical trials when the GLI reference equations were applied. Risk prediction models performed similarly in predicting mortality using both reference equations. Applying the GLI reference equations in patients with ILD leads to higher DLCO percentage predicted values and smaller lung volume percentage predicted values. While applying the GLI reference equations did not impact on prognostication, fewer patients met the clinical trial criteria for antifibrotic agents.
Link
Citation
Thorax 2024-10-16; 79(11)
Jornal Title
Thorax
ISSN
1468-3296

Files:

NameSizeformatDescriptionLink